Business
Lykos Therapeutics details how it is addressing questions raised by FDA advisors during a June 4 advisory meeting and how it will apply these insights to its Risk Evaluation and Mitigation Strategy.
Lykos Therapeutics addresses concerns from FDA Advisors about MDMA-assisted therapy and presents a forward looking plan.
The growing market for vaporizers that offers portable, disposable and convenient delivery systems for DMT, psilocybin, 2C-B and other psychedelic substances.
The executive director of the American Psychedelic Practitioners Association shares his vision for the professionalization of psychedelic-assisted therapy, as FDA approval seems likely this year.
The MAPS nonprofit remains the largest shareholder, but gives up controlling interest in MAPS PBC, as the for-profit company that seeks to commercialize MDMA therapy successfully attracts investors.
Three decades in the making, MAPS Public Benefit Corporation’s NDA for MDMA-assisted therapy for PTSD is the first for a psychedelic-assisted therapy.
Dan Love, co-founder of Beckley Waves, talks about the at-home ketamine business, the value of technical infrastructure, and the psychedelic field’s current consolidation.
A startup co-founded by a pioneering scientist is developing drug combination therapies which it says will make ketamine treatment more effective and accessible.
Filament Health produces botanical extracts used in the development of psychedelic drugs and therapies while complying with the Nagoya Protocol.
Two trailblazing service centers in Bend Oregon hope to provide affordable psilocybin experiences in different ways.
